A prospective study assessing the platelet-specific and non-specific immune response and in vivo platelet activation and blood clotting activation in healthy subjects who received ChAdOx1 or Ad26.COV2.S or BNT162b2
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 04 Aug 2022 New trial record
- 01 Jul 2022 Results published in the British Journal of Haematology